These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
66. Suppression of serum dehydroepiandrosterone sulfate levels by insulin: an evaluation of possible mechanisms. Nestler JE; Usiskin KS; Barlascini CO; Welty DF; Clore JN; Blackard WG J Clin Endocrinol Metab; 1989 Nov; 69(5):1040-6. PubMed ID: 2529264 [TBL] [Abstract][Full Text] [Related]
67. Metabolism of dehydroepiandrosterone sulfate (DS) in normal women and women with high DS concentrations. Haning RV; Carlson IH; Flood CA; Hackett RJ; Longcope C J Clin Endocrinol Metab; 1991 Dec; 73(6):1210-5. PubMed ID: 1835462 [TBL] [Abstract][Full Text] [Related]
68. [Estetrol determination in the serum after i.v. application of dehydroepiandrosterone sulfate in late pregnancy]. Schollberg K; Seiler E; Wagner S Acta Univ Palacki Olomuc Fac Med; 1981; 101():22-7. PubMed ID: 6211049 [No Abstract] [Full Text] [Related]
69. Is there a receptor for dehydroepiandrosterone or dehydroepiandrosterone sulfate? Widstrom RL; Dillon JS Semin Reprod Med; 2004 Nov; 22(4):289-98. PubMed ID: 15635497 [TBL] [Abstract][Full Text] [Related]
70. Effects of subchronic infusion of dehydroepiandrosterone sulfate on serum gonadotropin levels and ovarian function in the cynomolgus monkey. Kowalski W; Chatterton RT Fertil Steril; 1992 Apr; 57(4):912-20. PubMed ID: 1532562 [TBL] [Abstract][Full Text] [Related]
71. DHEA and the skeleton (through the ages). Gordon CM; Glowacki J; LeBoff MS Endocrine; 1999 Aug; 11(1):1-11. PubMed ID: 10668635 [TBL] [Abstract][Full Text] [Related]
72. Serum levels of dehydroepiandrosterone and its sulfate and the risk of developing bladder cancer. Gordon GB; Helzlsouer KJ; Comstock GW Cancer Res; 1991 Mar; 51(5):1366-9. PubMed ID: 1825478 [TBL] [Abstract][Full Text] [Related]
73. Dehydroepiandrosterone (DHEA): a fountain of youth? Baulieu EE J Clin Endocrinol Metab; 1996 Sep; 81(9):3147-51. PubMed ID: 8784058 [No Abstract] [Full Text] [Related]
75. Observations on neuroimmunomodulation as a novel therapeutic strategy in metastasis. Kumaria A Cancer Immunol Immunother; 2020 Oct; 69(10):2163-2164. PubMed ID: 32638081 [No Abstract] [Full Text] [Related]
76. Toward a 'chron-sensus' on neuroimmunomodulation, with 'modulation' operationally and inferentially defined. Cornélissen G; Halberg F Ann N Y Acad Sci; 1992 Apr; 650():60-7. PubMed ID: 1534975 [No Abstract] [Full Text] [Related]
77. Activation of dehydroepiandrosterone as a peroxisome proliferator by sulfate conjugation. Yamada J; Sakuma M; Ikeda T; Suga T Arch Biochem Biophys; 1994 Sep; 313(2):379-81. PubMed ID: 8080287 [No Abstract] [Full Text] [Related]
78. Studies on dehydroepiandrosterone (DHEA) and its sulphate during aging. Baulieu EE C R Acad Sci III; 1995 Jan; 318(1):7-11. PubMed ID: 7757806 [No Abstract] [Full Text] [Related]
79. Dehydroepiandrosterone and dehydroepiandrosterone sulfate: their relation to cardiovascular disease. Nafziger AN; Herrington DM; Bush TL Epidemiol Rev; 1991; 13():267-93. PubMed ID: 1837271 [No Abstract] [Full Text] [Related]
80. Specific binding of dehydroepiandrosterone sulfate to a cytoplasmic macromolecule in human fetal membrane. Sakyo K; Ito A; Hirakawa S; Mori Y Chem Pharm Bull (Tokyo); 1986 May; 34(5):2126-32. PubMed ID: 2943434 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]